DF-003

DRUG2 trials

Sponsors

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)

Conditions

HealthyROSAHSafety and Tolerability

Phase 1

Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

Active, not recruitingNCT05997641

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)Healthy, Safety and Tolerability

Start: 2023-09-15End: 2026-10-31Updated: 2026-06-03

Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients

RecruitingNCT06395285

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)ROSAH

Start: 2025-05-27End: 2026-11-01Target: 12Updated: 2026-06-05

Related Papers

Preliminary immunologic and clinical Phase 1b study outcomes from patients with ROSAH syndrome treated with the first-in-class ALPK1 inhibitor DF-003 2307448

The Journal of Immunology2026-07-28